{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027779","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.850784+00:00","generated_at":"2026-06-12T05:23:51.659506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead Q3 net loss widens to $103M; revenue drops 51%; milestones from GSK and Takeda","bullets":["Revenue $15.8M (down 51% YoY from $32.4M); net loss $102.9M (vs $72.0M loss); diluted EPS -$0.96 (vs -$0.68).","Cash and investments $494.5M vs $482.3M at Sept 30, 2022; total assets $795.9M.","Earned $30M milestone from GSK for Phase 2b start of ARO-HSD (NASH); $40M from Takeda for first patient in Phase 3 REDWOOD of fazirsiran.","Completed enrollment of PALISADE Phase 3 for ARO-APOC3; data readout expected Q2 2024.","R&D Day: ARO-RAGE inhaled dose of 184mg achieved 90% mean knockdown; TRiM platform shows CNS and adipose delivery advances."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027779","json":"https://secwatch.observer/filing/0001628280-23-027779.json","markdown":"https://secwatch.observer/filing/0001628280-23-027779.md","text":"https://secwatch.observer/filing/0001628280-23-027779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/0001628280-23-027779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/arwr-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:23:51.659506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}